Summary
The inhibitory effect of omeprazole on gastric acid secretion was tested in a group of patients on haemodialysis for chronic renal failure. Single 30 mg doses almost totally inhibited basal acid output on both dialysis and non-dialysis days. Plateau acid output was reduced by a mean of 77% and 90% on non-dialysis and dialysis days respectively. The absorption and pharmacokinetic profile of omeprazole were not affected by dialysis. Omeprazole was not recoverable from dialysis fluid. It is concluded that omeprazole is a potent inhibitor of gastric acid secretion in patients with chronic renal failure, and its effect is not influenced by haemodialysis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lind T, Cederberg C, Ekenved G, Haglund V, Olbe L (1983) Effect of omeprazole — a gastric proton pump inhibitor — on pentagastrin-stimulated acid secretion in man. Gut 24: 270–276
Howden CW, Forrest JAH, Reid JL (1984) Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 25: 707–710
Walt RP, Gomes M de FA, Wood EC, Logan LH, Pounder RE (1983) Effect of daily oral omeprazole on 24 hour intragastric acidity. Br Med J 287: 12–14
Gustavsson S, Loof L, Adami H-O, Nyberg A, Nyren O (1983) Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial. Lancet 2: 124–125
Ventkateswaran PS, Jeffers A, Hocken AG (1972) Gastric acid secretion in chronic renal failure. Br M J 4: 22–23
Shepherd AMN, Stewart WK, Wormsley KG (1973) Peptic ulceration in chronic renal failure. Lancet 1: 1357–1359
Howden CW, Reid JL (1984) Omeprazole, a gastric “protonpump” inhibitor: lack of effect on renal handling of electrolytes and urinary acidification. Eur J Clin Pharmacol 26: 639–640
Dubb JW, Stote RM, Familiar RG, Lee K, Alexander F (1978) Effect of cimetidine on renal function in normal man. Clin Pharmacol Ther 24: 76–83
Burgess E, Culter RE, Blair RD (1980) Cimetidine pharmacokinetics in haemodialysis patients and inhibition of creatinine secretion in healthy subjects. Clin Pharmacol Ther 27: 247 (abstract)
Flind AC, Rowley-Jones D (1979) Mental confusion and cimetidine. Lancet 1: 379
Totte J, Scharpe S, Verkert R, Neels H, Vanhueverbeek M, Smitz S, Rousseau JJ (1981) Neurological dysfunction associated with abnormal levels of cimetidine metabolite. Lancet 1: 1047
Howden CW, Meredith PA, Forrest JAH, Reid JL (1984) Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol 26: 641–643
Hassan M, Hobsley M (1970) Positioning of subject and of nasogastric tube during a gastric secretion study. Br Med J 1: 458–460
Mason MC, Giles GR, Clark CG (1969) Continuous intravenous pentagastrin as a stimulant of maximal gastric acid secretion. Gut 10: 34–38
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Howden, C.W., Payton, C.D., Meredith, P.A. et al. Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure. Eur J Clin Pharmacol 28, 637–640 (1985). https://doi.org/10.1007/BF00607907
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607907